Compositions that include extracellular matrix (ECM) materials having antiviral activity and methods of use thereof are disclosed. The compositions may be administered to a subject in need thereof, e.g., subject having a viral infection or being suspected of having a viral infection. The virus may be an enveloped virus, such as a coronavirus.

Compositions that include extracellular matrix (ECM) materials having antiviral activity and methods of use thereof are disclosed. The compositions may be administered to a subject in need thereof, e.g., subject having a viral infection or being suspected of having a viral infection. The virus may be an enveloped virus, such as a coronavirus.

An implantable medical product and method of use for substantially reducing or eliminating harsh biological responses associated with conventionally implanted medical devices, including inflammation, infection and thrombogenesis, when implanted in in a body of a warm blooded mammal. The bioremodelable pouch structure is configured and sized to receive, encase and retain an electrical medical device therein and to allow such device to be inserted into the internal region or cavity of the pouch structure; with the pouch structure formed from either. (a) first and second sheets, or (b) a single sheet having first and second sheet portions. After receiving the electrical device, the edges around the opening are closed by suturing or stapling. The medical device encased by the bioremodelable pouch structure effectively improves biological functions by promoting tissue regeneration, modulated healing of adjacent tissue or growth of new tissue when implanted in the body of the mammal.

The invention relates to improved culture methods for expanding epithelial stem cells and obtaining organoids, to culture media involved in said methods, and to uses of said organoids.

The invention relates to improved culture methods for expanding epithelial stem cells and obtaining organoids, to culture media involved in said methods, and to uses of said organoids.

Administering a pulmonary surfactant and a corticosteroid in a low dose is effective for the prophylaxis of bronchopulmonary dysplasia (BPD) in preterm neonates.

Administering a pulmonary surfactant and a corticosteroid in a low dose is effective for the prophylaxis of bronchopulmonary dysplasia (BPD) in preterm neonates.

Administering a pulmonary surfactant and a corticosteroid in a low dose is effective for the prophylaxis of bronchopulmonary dysplasia (BPD) in preterm neonates.

Described herein is a method of generating in-vitro differentiated airway basal cells and compositions thereof. Also described herein is a method of treating a pulmonary disease comprising administering the in-vitro differentiated airway basal cells and compositions thereof. In another aspect, described herein is a disease model comprising patient-derived or genetically modified in-vitro differentiated airway basal cells and compositions thereof.

Described herein is a method of generating in-vitro differentiated airway basal cells and compositions thereof. Also described herein is a method of treating a pulmonary disease comprising administering the in-vitro differentiated airway basal cells and compositions thereof. In another aspect, described herein is a disease model comprising patient-derived or genetically modified in-vitro differentiated airway basal cells and compositions thereof.